TABLE 2.
Clinical and pathologic factors associated with close margins in patients with ductal carcinoma-in situ treated with mastectomy (n = 810)
| Factors | Margins positive or ≤1 mm, n (%) | Margins 1.1–2.9 mm, n (%) | Margins ≥3 mm, n (%) | p value, overall | p value, positive or ≤1 versus ≥1.1 | p value, positive or ≤1 versus 1.1–2.9 |
|---|---|---|---|---|---|---|
| All patients | 59 (7.3) | 35 (4.3) | 716 (88.4) | |||
| Race | ||||||
| White | 38 (64.4) | 26 (74.3) | 536 (74.9) | |||
| African American | 12 (20.3) | 2 (5.7) | 71 (9.9) | |||
| Hispanic | 7 (11.9) | 3 (8.6) | 56 (7.8) | |||
| Asian/Pacific Islander | 2 (3.4) | 3 (8.6) | 41 (5.7) | |||
| Other | 0 (0) | 1 (2.8) | 12 (1.7) | 0.218 | 0.053 | 0.166 |
| Age | ||||||
| Median (range), years | 45 (22–77) | 50 (37–70) | 53 (20–88) | <0.001a | <0.001a | 0.008a |
| ≤50 years | 44 (74.6) | 19 (54.3) | 293 (40.9) | |||
| >50 years | 15 (25.4) | 16 (45.7) | 423 (59.1) | <0.001 | <0.001 | 0.043 |
| Menopausal statusb | ||||||
| Premenopausal | 37 (63.8) | 16 (45.7) | 226 (31.6) | |||
| Postmenopausal | 21 (36.2) | 19 (54.3) | 489 (68.4) | <0.001 | <0.001 | 0.088 |
| Initial presentationc | ||||||
| Clinical | 16 (27.1) | 9 (25.7) | 163 (22.9) | |||
| Radiological | 43 (72.9) | 26 (74.3) | 549 (77.1) | 0.719 | 0.474 | 0.882 |
| Largest recorded mammographic lesion dimension, cm, median (range)d | 6.0 (1.0–20) | 5.0 (0.8–9.8) | 3.0 (0.3–18) | <0.001a | <0.001a | 0.212a |
| Skin-sparing mastectomy | ||||||
| Yes | 42 (71.2) | 27 (77.1) | 400 (55.9) | |||
| No | 17 (28.8) | 8 (22.9) | 316 (44.1) | 0.005 | 0.032 | 0.527 |
| Immediate breast reconstruction | ||||||
| Yes | 51 (86.4) | 28 (80.0) | 455 (63.6) | |||
| No | 8 (13.6) | 7 (20.0) | 261 (36.4) | <0.001 | 0.001 | 0.410 |
| Contralateral prophylactic mastectomy | ||||||
| Yes | 15 (25.4) | 4 (11.4) | 114 (15.9) | |||
| No | 44 (74.6) | 31 (88.6) | 602 (84.1) | 0.119 | 0.053 | 0.102 |
| Largest recorded pathologic lesion size, cm, median (range)e | 5.1 (0.2–19) | 4.7 (1.5–17) | 2.0 (0.02–18) | <0.001a | <0.001a | 0.974a |
| Nuclear gradef | ||||||
| I or II | 18 (30.5) | 14 (40.0) | 319 (45.3) | |||
| III | 41 (69.5) | 21 (60.0) | 386 (54.7) | 0.081 | 0.031 | 0.345 |
| Multicentricg | ||||||
| Yes | 33 (62.3) | 18 (56.3) | 196 (35.6) | |||
| No | 20 (37.7) | 14 (43.8) | 355 (64.4) | <0.001 | <0.001 | 0.583 |
| Multifocalh | ||||||
| Yes | 27 (60.0) | 18 (56.3) | 193 (35.9) | |||
| No | 18 (40.0) | 14 (43.7) | 345 (64.1) | <0.001 | 0.002 | 0.742 |
| Comedoi | ||||||
| Yes | 29 (50.9) | 13 (38.2) | 210 (30.7) | |||
| No | 28 (49.1) | 21 (61.8) | 474 (69.3) | <0.001 | 0.002 | 0.242 |
| Necrosis | ||||||
| Yes | 42 (71.2) | 27 (77.1) | 315 (44.0) | |||
| No | 17 (28.8) | 8 (22.9) | 401 (56.0) | <0.001 | <0.001 | 0.527 |
| Estrogen receptor statusj | ||||||
| Yes | 31 (75.6) | 28 (93.3) | 301 (75.4) | |||
| No | 10 (24.4) | 2 (6.7) | 98 (24.6) | 0.082 | 0.876 | 0.049 |
a
Calculated by the Kruskal–Wallis test
b
Two patients were perimenopausal
c
Not available for four patients
d
Not available for 423 patients
e
Not available for 182 patients
f
Not available for 11 patients
g
Not available for 174 patients
h
Not available for 195 patients
i
Not available for 35 patients
j
Not available for 340 patients